{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:09:44Z","timestamp":1757452184153},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T00:00:00Z","timestamp":1374364800000},"content-version":"vor","delay-in-days":3003,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.curtheres.2005.06.008","type":"journal-article","created":{"date-parts":[[2011,2,19]],"date-time":"2011-02-19T09:26:36Z","timestamp":1298107596000},"page":"139-153","source":"Crossref","is-referenced-by-count":4,"title":["Ketolides in the treatment of community-acquired respiratory tract infections: A review"],"prefix":"10.1016","volume":"66","author":[{"given":"Martin S.","family":"Lipsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2005.06.008_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/srin.2000.18059","article-title":"The epidemiology of respiratory tract infections","volume":"15","author":"File","year":"2000","journal-title":"Semin Respir Infect."},{"key":"10.1016\/j.curtheres.2005.06.008_bib2","first-page":"853","article-title":"Antibiotic use in acute respiratory infections and the ways patients pressure physicians for a prescription","volume":"50","author":"Scott","year":"2001","journal-title":"J Fam Pract."},{"issue":"326","key":"10.1016\/j.curtheres.2005.06.008_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00000441-200312000-00012","article-title":"Current issues in the management of bacterial respiratory tract disease: The challenge of antibacterial resistance","author":"Dunbar","year":"2003","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.curtheres.2005.06.008_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","article-title":"The ketolides: A critical review","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.curtheres.2005.06.008_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.0070s3011.x","article-title":"Structure-activity relationships of ketolides vs. macrolides","volume":"7","author":"Douthwaite","year":"2001","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.curtheres.2005.06.008_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide-ketolide antibiotic binding site is formed by structures in domains 11 and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol."},{"key":"10.1016\/j.curtheres.2005.06.008_bib7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0149-2918(02)80002-9","article-title":"Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections","volume":"24","author":"Bishai","year":"2002","journal-title":"Clin Ther."},{"key":"10.1016\/j.curtheres.2005.06.008_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.15.3.430-438.2002","article-title":"Vancomycin resistance in staphylococci","volume":"15","author":"Srinivasan","year":"2002","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.curtheres.2005.06.008_bib9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/46.6.1017","article-title":"The in vitro activity of ABT773, a new ketolide antimicrobial agent","volume":"46","author":"Andrews","year":"2000","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl T1","key":"10.1016\/j.curtheres.2005.06.008_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/48.suppl_2.25","article-title":"Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens","volume":"48","author":"Hammerschlag","year":"2001","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl S1","key":"10.1016\/j.curtheres.2005.06.008_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/dkf810","article-title":"The PROTEKT surveillance study: Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections","volume":"50","author":"Hoban","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0163-4453(03)00123-3","article-title":"Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: Data from PROTEKT US 2000-01","volume":"48","author":"Doern","year":"2004","journal-title":"J Infect."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2005.06.008_bib13","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1093\/jac\/dkh313","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patientsacross the USA, in 2001\u20132002, as part of the PROTEKT US study","volume":"54","author":"Brown","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.42.4.945","article-title":"Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/dkh068","article-title":"Tissue kinetics of telithromycin, the first ketolide antibacterial","volume":"53","author":"Muller-Serieys","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkg154","article-title":"Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae","volume":"51","author":"Hammerschlag","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/AAC.48.2.605-607.2004","article-title":"Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae","volume":"48","author":"Jorgensen","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/02813439209014029","article-title":"Production of betalactamase by respiratory tract bacteria in children: Relationship to antibiotic use","volume":"10","author":"Molstad","year":"1992","journal-title":"Scand J Prim Health Care"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2005.06.008_bib21","doi-asserted-by":"crossref","first-page":"2A","DOI":"10.1177\/14732300020300S102","article-title":"Beta-lactam resistance: Clinical implications for pediatric patients","volume":"30","author":"Dajani","year":"2002","journal-title":"J Int Med Res."},{"key":"10.1016\/j.curtheres.2005.06.008_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3201\/eid0901.020172","article-title":"Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance","volume":"9","author":"Stratton","year":"2003","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.curtheres.2005.06.008_bib23","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.48.5.1882-1884.2004","article-title":"Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2005.06.008_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.curtheres.2005.06.008_bib25","series-title":"Ketek (telithromycin) tablets","year":"2004"},{"key":"10.1016\/j.curtheres.2005.06.008_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.curtheres.2005.06.008_bib27_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in acute maxillary sinusitis","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.curtheres.2005.06.008_bib27_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in acute maxillary sinusitis","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.curtheres.2005.06.008_bib27_3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in acute maxillary sinusitis","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.curtheres.2005.06.008_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol."},{"key":"10.1016\/j.curtheres.2005.06.008_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/ clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med."},{"key":"10.1016\/j.curtheres.2005.06.008_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations ofchronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res."},{"key":"10.1016\/j.curtheres.2005.06.008_bib31","series-title":"Abstracts of the 13th European Respiratory Society Meeting","article-title":"Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis","author":"Fogarty","year":"2003"},{"key":"10.1016\/j.curtheres.2005.06.008_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.curtheres.2005.06.008_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"van Rensburg","year":"2002","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.curtheres.2005.06.008_bib34","series-title":"Abstracts of the 41st Interscience Conference on Antimicro bial Agents and Chemotherapy","first-page":"449","article-title":"Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae","author":"Fogarty","year":"2001"},{"key":"10.1016\/j.curtheres.2005.06.008_bib35","series-title":"An open-label, multicenter, multinational, uncontrolled study of the efficacy and safety of 7 days of oral telithromycin (HMR 3647 800 mg once daily) in the treatment of community-acquired pneumonia due to Streptococcus pneumoniae in adolescents and adults","year":"2002"},{"key":"10.1016\/j.curtheres.2005.06.008_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of communityacquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.curtheres.2005.06.008_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clin Ther."},{"key":"10.1016\/j.curtheres.2005.06.008_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of communityacquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.curtheres.2005.06.008_bib39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate communityacquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.curtheres.2005.06.008_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jinf.2004.05.014","article-title":"Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: A pooled analysis","volume":"50","author":"Roos","year":"2005","journal-title":"J Infect."},{"key":"10.1016\/j.curtheres.2005.06.008_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1742-1241.2004.00344.x","article-title":"Telithromycin for the treatment of acute exacerbations of chronic bronchitis","volume":"59","author":"Fogarty","year":"2005","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.curtheres.2005.06.008_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/rmed.2003.1492","article-title":"Telithromycin in the treatment of community-acquired pneumonia: A pooled analysis","volume":"97","author":"Hagberg","year":"2003","journal-title":"Respir Med."},{"key":"10.1016\/j.curtheres.2005.06.008_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14740338.1.2.121","article-title":"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval","volume":"1","author":"Iannini","year":"2002","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.curtheres.2005.06.008_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mcp.2003.4","article-title":"Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects","volume":"73","author":"Demolis","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.curtheres.2005.06.008_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0924-8579(03)00128-6","article-title":"Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment","volume":"22","author":"Cantalloube","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.curtheres.2005.06.008_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0091270003262952","article-title":"Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment","volume":"44","author":"Shi","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.curtheres.2005.06.008_bib47","first-page":"1113","article-title":"Ketolides: A new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting","volume":"78","author":"Clark","year":"2003"},{"key":"10.1016\/j.curtheres.2005.06.008_bib48","series-title":"Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones","article-title":"Telithromycin (HMR 3647), a new ketolides antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives","author":"Scholtz","year":"2000"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2005.06.008_bib49","first-page":"267","article-title":"Telithromycin (HMR 3647) does not interact with the CYP2D6 substrate paroxetine","volume":"7","author":"Lippert","year":"2001","journal-title":"Clin Microbiol Infect."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2005.06.008_bib50","first-page":"267","article-title":"Effect of gastric pH on the bioavailability of telithromycin (HNIR 3647)","volume":"7","author":"Lippert","year":"2001","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.curtheres.2005.06.008_bib51","first-page":"933","article-title":"Drug-grapefruit juice interactions","volume":"75","author":"Kane","year":"2000"},{"key":"10.1016\/j.curtheres.2005.06.008_bib52","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Efficacy and safety of telithromycin in 34,929 patients with respiratory tract infections","author":"Lorenz","year":"2004"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X05000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X05000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:33:35Z","timestamp":1685954015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X05000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0011393X05000615"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2005.06.008","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}